Fecal M2-PK in children with Crohn's disease: A preliminary report

Digestive Diseases and Sciences

Volumn 57, Issue 8, 2012, Pages 2166-2170

  Day, A S ^a,b,c   Judd, T ^b   Lemberg, D A ^b,c   Leach, S T ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Children; Crohn's disease; Disease activity; M2 PK; Stool markers

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL RADIOGRAPHY; HISTOLOGY; HUMAN; INFLAMMATION; PRIORITY JOURNAL; SCORING SYSTEM; SERUM;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FECES; FEMALE; HUMANS; INFANT; MALE; PYRUVATE KINASE;

EID: 84866392294     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2215-3     Document Type: Article

References (18)

1. Beattie RM, Croft NM, Fell JM, et al. Inflammatory bowel disease. Arch Dis Child. 2006;91:426-432.
2. Griffiths AM, Buller HB. Inflammatory bowel diseases. In: Walker WA, Hamilton JR, et al., eds. Pediatric Gastrointestinal Disease, Chapter 41. Hamilton: BC Decker; 2000:613-652.
3. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119:1113-1119.
4. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. An update of faecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493-1499.
5. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-1091.
6. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359-366.
7. Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. FecalM2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374-1378.
8. Czub E, Herzig K-H, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147-1150.
9. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig K-H. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005;40:1493-1494.
10. Haug U, Wente MN, Seiler CM, et al. Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. Clin Chem. 2006;52:782-784.
11. Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91:980-984.
12. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207-1212.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
14. Hyams J, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
15. de Jong NSH, Leach ST, Day AS. Faecal S100A12: a novel noninvasive marker of gastrointestinal inflammation in children. Inflamm Bowel Dis. 2006;12:566-572.
16. Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther. 2002;16:857-867.
17. Jeffrey J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (Tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Inflamm Bowel Dis. 2009;15:1630-1634.
18. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259-263.